Topical tranexamic acid versus hydroquinone for patients presenting with melasma

Arsilah Erum, Faria Asad, Rutaba Kiran, Ijaz Hussain, Farheen Hassan, Bushra Bashir

Abstract


Objective To compare the outcome with topical tranexamic acid versus hydroquinone for management of patients presenting with melasma.

 

Methods The present study was conducted in the outpatient department of dermatology unit 1. 354 patients fulfilling selection criteria were enrolled and divided in two groups. In group A, patients were prescribed topical cream of 5% TA and in group B, patients were prescribed topical cream of 2% hydroquinone. MASI score was assessed at presentation and at 4 weeks of follow up.

 

Results In this study the mean age of cases in Tranexamic acid group was 35.42±10.68 years and in Hydroquinone group was 36.25 ±10.42 years. In Tranexamic acid there were 13(7.3%) male and 164(92.7%) female cases and in Hydroquinone group there were 26(14.7%) male and 151(85.3%) female cases. Mean duration of pigmentation in Tranexamic acid group was 6.45±3.10 months and in Hydroquinone group was 6.50±3.02 months. The mean MASI score at baseline in Tranexamic acid group was 36.14 ± 6.85 and in Hydroquinone group was 36.61 ± 6.81. The mean MASI score at last follow up in Tranexamic acid group was 23.68±7.96 and in Hydroquinone group was 19.32±8.33. The mean MASI score was statistically less in Hydroquinone group as compared to Tranexamic acid group, p-value < 0.01. In Tranexamic acid group 39(22%) cases had side effects and in Hydroquinone group 83(46.9%) cases had side effects.

 

Conclusion This study concludes that MASI score was significantly reduced in hydroquinone group but cases in topical tranexamic acid group developed less side effects. So, further studies are required to establish the use of topical tranexamic acid.

 


Keywords


Melasma, MASI, topical tranexamic acid, hydroquinone

Full Text:

PDF

References


Tse TW, Hui E. Tranexamic acid: an important adjuvant in the treatment of melasma. J Cosmet Dermatol. 2013;12(1):57-66.

Aamir S, Naseem R. Oral tranexamic acid in treatment of melasma in Pakistani population: a pilot study. J Pak Assoc Dermatol. 2014;24(3):198-203.

Shankar K, Godse K, Aurangabadkar S, Lahiri K, Mysore V, Ganjoo A, et al. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Therap. 2014;4(2):165-86.

Sofen B, Prado G, Emer J. Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion. Skin Ther Letter. 2016;21(1):1-7.

Wu S, Shi H, Wu H, Yan S, Guo J, Sun Y, et al. Treatment of melasma with oral administration of tranexamic acid. Aesthet Plast Surg. 2012;36(4):964-70.

Tan AWM, Sen P, Chua SH, Goh BK. Oral tranexamic acid lightens refractory melasma. Australas J Dermatol. 2016;58(3):105-8.

Lee HC, Thng TGS, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. J Am Acad Dermatol. 2016;75(2):385-92.

Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci. 2014;19(8):753-7.

Atefi N, Dalvand B, Ghassemi M, Mehran G, Heydarian A. Therapeutic Effects of Topical Tranexamic Acid in Comparison with Hydroquinone in Treatment of Women with Melasma. Dermatol Ther. 2017;7(3):417-24.

Banihashemi M, Zabolinejad N, Jaafari MR, Salehi M, Jabari A. Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma. J Cosmet Dermatol. 2015;14(3):174-7.


Refbacks

  • There are currently no refbacks.


ISSN: 1560-9014